Table 2.
Disease characteristics and medications
| Nonobese HFpEF | Obese HFpEF | |
|---|---|---|
| Disease characteristics, n/% | ||
| NYHA class II | 11/79 | 26/65 |
| NYHA class III | 2/14 | 12/30 |
| NYHA class IV | 0/0 | 2/5 |
| Diabetes | 2/14 | 11/28 |
| COPD | 1/7 | 3/8 |
| CAD | 5/36 | 9/23 |
| Hypertension | 9/64 | 29/73 |
| Hyperlipidemia | 8/57 | 14/35 |
| Medications | ||
| β-Blockers | 7/50 | 22/55 |
| ACEi | 1/7 | 14/35 |
| ARB | 4/29 | 11/28 |
| Loop diuretics | 11/79 | 30/75 |
| Aldosterone antagonists | 7/50 | 33/83* |
| Statin | 9/64 | 26/65 |
| Ca2+ channel blocker | 3/21 | 10/25 |
| Mean Rx types taken ± SE | 3.2 ± 1.2 | 3.8 ± 1.3 |
| Subjects taking Rx, % | 100 | 100 |
A χ2 test was performed between groups (α < 0.05). *P < 0.05 vs. nonobese HFpEF. Means ± SD. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; HFpEF, heart failure with preserved ejection fraction; NYHA class, New York Heart Association functional classification; Rx, prescription.